Results 191 to 200 of about 127,904 (323)

Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines.

open access: yesJournal of Medicinal Chemistry, 2014
Julien Louvel   +10 more
semanticscholar   +1 more source

Glabridin‐Gold(I) Complex as a Novel Immunomodulatory Agent Targeting TrxR and MAPK Pathways for Synergistic Enhancement of Antitumor Immunity

open access: yesAdvanced Science, Volume 12, Issue 41, November 6, 2025.
Complex 6d could promote tumor immunogenicity by targeting thioredoxin reductase (TrxR) and remodel immunosuppressive microenvironment by the mitogen‐activated protein kinase (MAPK) pathway inhibition simultaneously. This study provides a novel approach to develop metal immunomodulatory agents by designing gold complexes incorporating natural products,
Zhaoran Wang   +10 more
wiley   +1 more source

A Chemical Biological Approach to Study G Protein-Coupled Receptors: Labeling the Adenosine A1 Receptor Using an Electrophilic Covalent Probe. [PDF]

open access: yesACS Chem Biol, 2022
Beerkens BLH   +7 more
europepmc   +1 more source

Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to α1‐adrenoceptor stimulation in vivo

open access: yesBritish Journal of Pharmacology, 2015
S. Puhl   +7 more
semanticscholar   +1 more source

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

open access: yesCancer Communications, Volume 45, Issue 11, Page 1456-1495, November 2025.
Abstract Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to ...
Jingwen Hu   +4 more
wiley   +1 more source

The Second Extracellular Loop of the Adenosine A1 Receptor Mediates Activity of Allosteric Enhancers

open access: yesMolecular Pharmacology, 2014
Dylan P Kennedy   +10 more
semanticscholar   +1 more source

Cardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin

open access: yesDrug Development Research, Volume 86, Issue 7, November 2025.
ABSTRACT Vasoinhibin is a potent antiangiogenic protein that blocks the activation of endothelial nitric oxide synthase (eNOS) in response to vascular endothelial growth factor, bradykinin, and acetylcholine (ACh). In this regard, VIAN‐c4551, a new synthetic vasoinhibin analog, has therapeutic potential for targeting angiogenesis in oncology and ...
Miguel A. García‐González   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy